Caliway Biopharmaceuticals, a Taiwan-based biopharmaceutical company focusing on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, announced on Wednesday that it has started patient recruitment for its CBL-0204 Phase 2b study.
The study has been approved by the US FDA and will enrol 100 subjects in 14 clinical sites in the United States and Australia.
CBL-0204, a Phase 2b study, is assessing the efficacy, safety and tolerability of CBL-514 injection, the company's leading candidate drug, in decreasing abdominal subcutaneous fat. The study is enrolling 100 adult patients with mild, moderate, or severe abdominal subcutaneous fat as evaluated by the abdominal fat rating scale (AFRS). The study's primary efficacy endpoint is the percentage of patients with around one-grade improvement reported by the investigator assessing with the AFRS.
The CBL-0204 Phase 2b study should be completed in the second quarter of 2024 and the top-line results are expected in the third quarter of 2024. The Phase three pivotal study is expected to be implemented in 2024.
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic